NICE turns down Tecentriq in bladder cancer but suggests Roche try again for some patients

2nd August 2017 Uncategorised 0

Roche and England’s drug cost watchdog NICE are again in an arm-wrestling contest, this time over the use of Roche’s cancer drug Tecentriq for metastatic urothelial cancer.

More: NICE turns down Tecentriq in bladder cancer but suggests Roche try again for some patients
Source: fierce